Soluble TNF-α receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer

Gene Therapy

Volumn 17, Issue 11, 2010, Pages 1400-1410

  Moulay, G ^a   Masurier, C ^a   Bigey, P ^b   Scherman, D ^a,b   Kichler, A ^a,b  

^a GÉNÉTHON   (France)

^b Centre National de la Recherche Scientifique   (France)

Author keywords

adeno associated virus; dystrophic muscle; gene therapy; immune response; TNF receptor

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; PARVOVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TRANSGENE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; CELLS, CULTURED; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR NECROSIS FACTOR-ALPHA;

ADENO-ASSOCIATED VIRUS; MURINAE; MUS;

EID: 78149470601     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.94     Document Type: Article

References (34)

1. Balaban B, Matthews DJ, Clayton GH, Carry T. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005; 84: 843-850.
2. Porter JD, Khanna S, Kaminski HJ, Rao JS, Merriam AP, Richmonds CR et al. A chronic inflammatory response dom¬inates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 2002; 11: 263-272.
3. Porreca E, Guglielmi MD, Uncini A, Di Gregorio P, Angelini A, Di Febbo C et al. Haemostatic abnormalities, cardiac involve¬ment and serum tumor necrosis factor levels in X-linked dystrophic patients. Thromb Haemost 1999; 81: 543-546.
4. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. Faseb J 2005; 19: 362-370.
5. Grounds MD, Torrisi J. Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. Faseb J 2004; 18: 676-682.
6. Ghosh A, Yue Y, Duan D. Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. J Gene Med 2006; 8: 298-305.
7. Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 5804-5809.
8. Arruda VR, Hagstrom JN, Deitch J, Heiman-Patterson T, Camire RM, Chu K et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 2001; 97: 130-138.
9. Song S, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95: 14384-14388.
10. Kreiss P, Bettan M, Crouzet J, Scherman D. Erythropoietin secretion and physiological effect in mouse after intramuscular plasmid DNA electrotransfer. J Gene Med 1999; 1: 245-250.
11. Deleuze V, Scherman D, Bureau MF. Interleukin-10 expression after intramuscular DNA electrotransfer: kinetic studies. Biochem Biophys Res Commun 2002; 299: 29-34.
12. Silvestre JS, Mallat Z, Duriez M, Tamarat R, Bureau MF, Scherman D et al. Antiangiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb. Circ Res 2000; 87: 448-452.
13. Bloquel C, Bessis N, Boissier MC, Scherman D, Bigey P. Gene therapy of collagen-induced arthritis by electrotransfer of human tumor necrosis factor-alpha soluble receptor I variants. Hum Gene Ther 2004; 15: 189-201.
14. Bloquel C, Bejjani R, Bigey P, Bedioui F, Doat M, BenEzra D et al. Plasmid electrotransfer of eye ciliary muscle: principles and therapeutic efficacy using hTNF-alpha soluble receptor in uveitis. Faseb J 2006; 20: 389-391.
15. Pierno S, Nico B, Burdi R, Liantonio A, Didonna MP, Cippone V et al. Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morpholo¬gical indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol Appl Neurobiol 2007; 33: 344-359.
16. Hartigan-O'Connor D, Kirk CJ, Crawford R, Mule JJ, Chamberlain JS. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther 2001; 4: 525-533.
17. Wang L, Dobrzynski E, Schlachterman A, Cao O, Herzog RW. Systemic protein delivery by muscle-gene transfer is limited by a local immune response. Blood 2005; 105: 4226-4234.
18. Turk R, Sterrenburg E, van der Wees CG, de Meijer EJ, de Menezes RX, Groh S et al. Common pathological mechanisms in mouse models for muscular dystrophies. Faseb J 2006; 20: 127-129.
19. Egashira K, Koyanagi M, Kitamoto S, Ni W, Kataoka C, Morishita R et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. Faseb J 2000; 14: 1974-1978.
20. Khoury M, Escriou V, Courties G, Galy A, Yao R, Largeau C et al. Efficient suppression of murine arthritis by combined antic-ytokine small interfering RNA lipoplexes. Arthritis Rheum 2008; 58: 2356-2367.
21. Kuru S, Inukai A, Kato T, Liang Y, Kimura S, Sobue G. Expression of tumor necrosis factor-alpha in regenerating muscle fibers in inflammatory and non-inflammatory myopa-thies. Acta Neuropathol 2003; 105: 217-224.
22. Hodgetts S, Radley H, Davies M, Grounds MD. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul Disord 2006; 16: 591-602.
23. Abmayr S, Gregorevic P, Allen JM, Chamberlain JS. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. Mol Ther 2005; 12: 441-450.
24. Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Tanouchi A, Yama-moto H, Li J et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther 2002; 9: 1576-1588.
25. Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther 2007; 18: 18-26.
26. Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 2007; 15: 1160-1166.
27. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 2005; 12: 1453-1464.
28. Squire S, Raymackers JM, Vandebrouck C, Potter A, Tinsley J, Fisher R et al. Prevention of pathology in mdx mice by expression of utrophin: analysis using an inducible transgenic expression system. Hum Mol Genet 2002; 11: 3333-3344.
29. Denti MA, Rosa A, D'Antona G, Sthandier O, De Angelis FG, Nicoletti C et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci USA 2006; 103: 3758-3763.
30. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91.
31. Miura P, Jasmin BJ. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we? Trends Mol Med 2006; 12: 122-129.
32. Wang M, Orsini C, Casanova D, Millan JL, Mahfoudi A, Thuillier V. MUSEAP, a novel reporter gene for the study of long-term gene expression in immunocompetent mice. Gene 2001; 279: 99-108.
33. Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J Virol 2001; 75: 1824-1833.
34. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.